PFE vs PG: Which Is the Better Buy?
Side-by-side comparison of Pfizer Inc. and The Procter & Gamble Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-05.
Pfizer Inc. · Healthcare
$26.33
+35.4% upside to fair value
Grade B
VS
The Procter & Gamble Company · Consumer Defensive
$143.45
+13.8% upside to fair value
Grade B
High Quality
QuantHub Verdict
PFE has more upside to fair value
(+35.4%).
PFE trades at a lower forward P/E
(19.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
PFE |
PG |
| Current Price |
$26.33 |
$143.45 |
| Fair Value Estimate |
$35.65 |
$163.27 |
| Upside to Fair Value |
+35.4%
|
+13.8%
|
| Market Cap |
$149.8B |
$334.0B |
| Forward P/E |
19.3x
|
20.8x
|
| EV / EBITDA |
12.9x
|
15.4x
|
| Price / Sales |
2.4x
|
3.9x
|
| Price / FCF |
16.5x
|
22.2x
|
| Revenue Growth YoY |
-1.2%
|
+7.4%
|
| Gross Margin |
70.3%
|
50.3%
|
| Operating Margin |
24.7%
|
23.2%
|
| Return on Equity |
8.7%
|
31.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
6.06%
|
4.5%
|
| Analyst Consensus |
Hold
|
Buy
|
Investment Thesis
Pfizer Inc. is a leading global pharmaceutical company specializing in drug manufacturing with a strong presence in vaccines, oncology, and primary care. The company benefits from a seasoned leadership team under CEO Albert Bourla, who has driven a strategic transformation focusing on science-driven innovation and portfolio optimization. Despite a high gross margin of 70.3% and solid operating ma…
The Procter & Gamble Company is a leading consumer defensive firm specializing in household and personal products with a diversified portfolio across fabric and home care, baby and family care, beauty, health care, and grooming segments. The business quality is high, supported by durable brands, strong margins with a 50.3% gross margin and 19.2% net margin, and consistent earnings growth evidence…
Accumulation Zones
| Metric |
PFE |
PG |
| Zone Low |
$26.74 |
$122.45 |
| Zone High |
$30.30 |
$138.78 |
| In Buy Zone? |
Yes
|
No
|